z-logo
Premium
Two‐Dimensional Antimonene‐Based Photonic Nanomedicine for Cancer Theranostics
Author(s) -
Tao Wei,
Ji Xiaoyuan,
Zhu Xianbing,
Li Li,
Wang Junqing,
Zhang Ye,
Saw Phei Er,
Li Wenliang,
Kong Na,
Islam Mohammad Ariful,
Gan Tian,
Zeng Xiaowei,
Zhang Han,
Mahmoudi Morteza,
Tearney Guillermo J.,
Farokhzad Omid C.
Publication year - 2018
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201802061
Subject(s) - materials science , nanotechnology , nanomedicine , nanomaterials , photothermal therapy , photonics , drug delivery , nanocarriers , nanoparticle , optoelectronics
Antimonene (AM) is a recently described two‐dimensional (2D) elemental layered material. In this study, a novel photonic drug‐delivery platform based on 2D PEGylated AM nanosheets (NSs) is developed. The platform's multiple advantages include: i) excellent photothermal properties, ii) high drug‐loading capacity, iii) spatiotemporally controlled drug release triggered by near‐infrared (NIR) light and moderate acidic pH, iv) superior accumulation at tumor sites, v) deep tumor penetration by both extrinsic stimuli (i.e., NIR light) and intrinsic stimuli (i.e., pH), vi) excellent multimodal‐imaging properties, and vii) significant inhibition of tumor growth with no observable side effects and potential degradability, thus addressing several key limitations of cancer nanomedicines. The intracellular fate of the prepared NSs is also revealed for the first time, providing deep insights that improve cellular‐level understanding of the nano–bio interactions of AM‐based NSs and other emerging 2D nanomaterials. To the best of knowledge, this is the first report on 2D AM‐based photonic drug‐delivery platforms, possibly marking an exciting jumping‐off point for research into the application of 2D AM nanomaterials in cancer theranostics.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here